EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANTES deficiency attenuates autoantibody-induced glomerulonephritis



RANTES deficiency attenuates autoantibody-induced glomerulonephritis



Journal of Clinical Immunology 31(1): 128-135



Experimental autoimmune nephritis in mice and spontaneous lupus nephritis are both associated with elevated expression of several chemokines in the kidneys. Nevertheless, the role that different chemokines play in mediating renal inflammation is far from complete. This study focuses on elucidating the functional role of RANTES, a chemokine that has been noted to be hyper-expressed within the kidneys, both in experimental renal disease as well as in spontaneous lupus nephritis. To elucidate if RANTES was essential for immune-mediated glomerulonephritis, DBA/1 mice that are highly sensitive to nephrotoxic serum nephritis were rendered RANTES-deficient and then tested for disease susceptibility. Nephritis-sensitive DBA/1 mice expressed more RANTES within the diseased kidneys. Compared to wild-type DBA/1 mice, RANTES-deficient DBA/1 mice developed significantly less proteinuria, azotemia, and renal inflammation, with reduced crescent formation and tubulo-interstitial nephritis. These findings indicate that RANTES ablation attenuates immune-mediated nephritis and suggest that this chemokine could be a potential therapeutic target in these diseases.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333226

Download citation: RISBibTeXText

PMID: 20886281

DOI: 10.1007/s10875-010-9470-x



Related references

STAT4 deficiency reduces autoantibody production and glomerulonephritis in a mouse model of lupus. Clinical Immunology 120(2): 189-198, 2006

Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model. Arthritis and Rheumatism 62(7): 1921-1932, 2010

P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. Journal of the American Society of Nephrology 20(6): 1275-1281, 2009

T-bet deficiency attenuates renal injury in experimental crescentic glomerulonephritis. Journal of the American Society of Nephrology 19(3): 477-485, 2008

Matrix metalloproteinase-12 (MMP-12) deficiency attenuates experimental crescentic anti-GBM glomerulonephritis. Nephrology (): -, 2016

IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice. Biology Direct 7: 3-3, 2012

Expression of murine Rantes in cultured mesangial cells and in glomeruli from kidneys with experimentally induced glomerulonephritis. Onkologie 15(SUPPL 1): 34-35, 1992

Tubular deficiency of von Hippel-Lindau attenuates renal disease progression in anti-GBM glomerulonephritis. American Journal of Pathology 179(5): 2177-2188, 2012

Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus. Journal of Immunology 183(10): 6207-6216, 2009

Curcumin attenuates the expression and secretion of RANTES after spinal cord injury in vivo and lipopolysaccharide-induced astrocyte reactivation in vitro. Journal of Neurotrauma 28(7): 1259-1269, 2012

CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice. Journal of Neuroimmune Pharmacology 3(4): 275-285, 2008

Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. Journal of Immunology 177(8): 5687-5696, 2006

Deficiency of pro-apoptotic Hrk attenuates programmed cell death in the developing murine nervous system but does not affect Bcl-x deficiency-induced neuron apoptosis. Journal of Histochemistry and Cytochemistry 59(11): 976-983, 2011

RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted anti-atherosclerotic therapy. 2007

RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted anti-atherosclerotic therapy. Thrombosis and Haemostasis 99(4): 794-795, 2008